Dual Antiplatelet Therapy, Platelet Reactivity
Conditions
Brief summary
to assess whether cessation of 12 months DAPT regimen containing Ticagrelor results in a hyperreactive phase of platelet function
Detailed description
the study will be composed of a cohort of patients , who completed 12 months of DAPT with Ticagrelor (standard recommended dose for ACS - 90 mg BID), did not experience any clinical or adverse event during this time period and are about to discontinue Ticagrelor. We intend to measure the platelet reactivity for each patient on 4 time points - prior to cessation of Ticagrelor (i.e. while still on DAPT) and 1,4 and 12 weeks post discontinuation of therapy. There will not be a control group.
Interventions
assessment of platelet aggregation using the VerifyNow purinergic receptor P2Y, G-protein coupled, 12 (P2Y12) platelet function assay (Accumetrics, San Diego, California)
Sponsors
Rabin Medical Center
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
No
Inclusion criteria
* Age\>18 * underwent coronary stent implantation due to ACS * completed 12 month of DAPT regimen containing Ticagrelor at standard dose (90 mg BID)
Exclusion criteria
* any ischemic or bleeding events while under Ticagrelor * any other Ticagrelor associated adverse effects * planned for continuation of Ticagrelor for more than 12months post stenting according to the judgment of the attending physician. * Unable to make informed consent .
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| platelet reactivity | from 1 week prior to 12 weeks post DAPT cessation |
Countries
Israel
Contacts
Primary ContactGuy Witberg, MD
Backup ContactEli Lev, MD
Outcome results
None listed